Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
QuintilesIMS
Queensland Health
Johnson and Johnson
Accenture

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,592,253

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,592,253 protect, and when does it expire?

Patent 9,592,253 protects LOKELMA and is included in one NDA.

This patent has sixteen patent family members in sixteen countries.

Summary for Patent: 9,592,253
Title:Extended use zirconium silicate compositions and methods of use thereof
Abstract: The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.
Inventor(s): Keyser; Donald Jeffrey (Southlake, TX), Guillem; Alvaro F. (Lantana, TX)
Assignee: ZS PHARMA, INC. (Coppell, TX)
Application Number:14/883,428
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Process;

Drugs Protected by US Patent 9,592,253

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-001 May 18, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA IN ADULTS ➤ Sign Up
Astrazeneca Pharms LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-002 May 18, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HYPERKALEMIA IN ADULTS ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,592,253

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 106369 ➤ Sign Up
Australia 2016338753 ➤ Sign Up
Brazil 112018007189 ➤ Sign Up
Canada 3000950 ➤ Sign Up
Chile 2018000916 ➤ Sign Up
China 108137620 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
UBS
Deloitte
McKesson
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.